Please login to the form below
Viatris
This page shows the latest Viatris news and features for those working in and with pharma, biotech and healthcare.
Pfizer's basic instincts
It happened to coincide with a blizzard of emails from friends who work for parts of Pfizer or for Mylan and now have Viatris.com addresses. ... Signalling strategy. On the surface, both the Pfizer logo change and the Viatris name change are just the
Latest news
-
Pfizer, Mylan move ahead with generics merger and spin-out
Now that the FTC has formally cleared the merger, the new firm, Viatris, will become a generics giant, with Pfizer owning 57% and Mylan owning 43%. ... Today’s approval represents the final significant milestone towards the creation of Viatris and the
-
COVID-19 delays Pfizer, Mylan’s generics merger and spin-out
Pfizer’s plan to spin out its Upjohn generic drugs business into a joint venture with Mylan called Viatris was formerly due to complete in the middle of this year.
-
Vyndaqel a bright spot as Pfizer comes under pressure
The results come ahead of Pfizer’s plan to spin out its Upjohn generic drugs business into a joint venture with Mylan called Viatris, due to complete in the middle of
-
Meda builds marketing muscle
Meda will pay Ä583m for Viatris shares and assume net debt, including pension provisions and similar obligations, of Ä167m. ... Meda, which currently has no manufacturing facilities, will be looking to utilise Viatris' production capabilities for
-
New accounts: October
central. Viatris Consumer Brands. Osteo-life. Calcium supplement. hsdcommunications.
More from news
Approximately 1 fully matching, plus 7 partially matching documents found.
Latest Intelligence
-
Changing an organisation’s microfoundations – why capabilities count
Imagine, for example, Alexion’s rare disease business model trying to compete with, say, Viatris in generic small molecules, or vice versa.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
- Account Manager, 6 month contract, Healthcare Brand communicatio...
- Highly competitive salary
- Home Based Account Manager, Medical Communications, UK, Pharma/M...
- Highly competitive salary
- Account Manager, Healthcare Marketing Creative Agency, Fixed ter...
- Highly competitive salary
- Senior Medical Copywriter - Highly Awarded Advertising Agency
- £50,000 - £60,000 yearly
- Account Director, Healthcare Marketing Creative Agency, Fixed te...
- Highly competitive salary
- Market Access Director, six figure base salary and £5K joining b...
- Highly competitive salary
- Novartis receives EC approval for Cosentyx in hidradenitis suppurativa
- BMS and Janssen’s antithrombotic granted FDA fast track designation
- Sanofi's frexalimab shows promise in relapsing forms of MS
- Amgen reports positive results for Otezla in psoriatic arthritis
- EMA recommends revoking marketing authorisation for Novartis’ sickle cell disease drug
- Seqera Labs and Genomics England partner to progress genomic research
- Pfizer’s antibiotic combination shows promise in treating multi-drug resistant infections
- Supporting the most vulnerable: why pharma should get behind the NHS’ healthcare equity campaign
- Healing the Healers
- The (inevitable) digital transformation of Medical Affairs
- Novartis receives EC approval for Cosentyx in hidradenitis suppurativa
- Pfizer’s RSV vaccine approved by FDA for older adults
No results were found
PMHub
Oxford University Press
Oxford University Press publishes over 100 prestigious, highly cited, and authoritative medical journals, many in collaboration with some of the...
Latest intelligence
- Healing the Healers
- Because if we do not heal the healers, who is going to heal us?...
- The (inevitable) digital transformation of Medical Affairs
- It’s not a question of ‘if,’ it’s a question of ‘when.’...
- Oncology eBook: Reducing the care gap in cancer prevention, diagnosis, and treatment
- Despite significant innovation in the oncology landscape, there is a growing care gap preventing patients accessing and benefiting from innovations in cancer treatment. In this new publication, our oncology experts...
